SEIKAGAKU CORPORATION Logo

SEIKAGAKU CORPORATION

A research pharma company using glycoscience to develop drugs for orthopedic & ophthalmic diseases.

4548 | T

Overview

Corporate Details

ISIN(s):
JP3414000004
LEI:
Country:
Japan
Address:
千代田区丸の内一丁目6番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Seikagaku Corporation is a research-driven pharmaceutical company specializing in glycoscience. The company engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices, with a primary focus on glycoconjugates like glycosaminoglycans (GAGs). Its main therapeutic areas include orthopedic disorders and ophthalmic diseases, offering products such as joint function improving agents. Seikagaku oversees its product lifecycle from in-house drug discovery and clinical trials to regulatory approval and commercial production, leveraging its specialized expertise in the field of complex carbohydrates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 06:56
Registration Form
確認書
Japanese 8.1 KB
2025-11-12 06:55
Interim Report
半期報告書-第80期(2025/04/01-2026/03/31)
Japanese 196.8 KB
2025-06-24 08:14
Post-Annual General Meeting Information
臨時報告書
Japanese 23.0 KB
2025-06-23 06:58
Governance Information
内部統制報告書-第79期(2024/04/01-2025/03/31)
Japanese 22.6 KB
2025-06-23 06:57
Registration Form
確認書
Japanese 8.0 KB
2025-06-23 06:56
Annual Report
有価証券報告書-第79期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2024-11-12 06:58
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-12 06:56
Interim Report
半期報告書-第79期(2024/04/01-2025/03/31)
Japanese 191.1 KB
2024-06-27 06:53
Governance Information
内部統制報告書-第78期(2023/04/01-2024/03/31)
Japanese 21.9 KB
2024-06-27 06:52
Registration Form
確認書
Japanese 8.0 KB
2024-06-27 06:51
Annual Report
有価証券報告書-第78期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-06-25 04:10
Post-Annual General Meeting Information
臨時報告書
Japanese 23.7 KB
2024-02-14 08:57
Quarterly Report
四半期報告書-第78期第3四半期(2023/10/01-2023/12/31)
Japanese 165.1 KB
2024-02-14 08:57
Report Publication Announcement
確認書
Japanese 8.0 KB
2023-11-14 05:06
Report Publication Announcement
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all SEIKAGAKU CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SEIKAGAKU CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SEIKAGAKU CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Cartesian Therapeutics, Inc. Logo
Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.
United States of America
RNAC
CASI Pharmaceuticals, Inc. Logo
Develops and commercializes drugs for oncology, transplant, and autoimmune disease.
United States of America
CASI
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
United States of America
SAVA
CATALYST PHARMACEUTICALS, INC. Logo
Advancing therapies for rare neuromuscular and neurological diseases like LEMS.
United States of America
CPRX
cbdMD, Inc. Logo
Produces & distributes lab-tested CBD wellness products for people and pets.
United States of America
YCBD
CDT Equity Inc. Logo
Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.
United States of America
CDT
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom
CEL
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America
CELC
Celemics, Inc. Logo
Develops custom NGS panels and bioinformatics for research and clinical diagnostics.
South Korea
331920
Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.
South Korea
308430

Talk to a Data Expert

Have a question? We'll get back to you promptly.